0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > CEACAM-8

CEACAM-8

Brief Information

Name:Non specific cross-reacting antigen 95
Target Synonym:Non-specific cross-reacting antigen NCA-95,CGM6,Carcinoembryonic Antigen Gene Family Member 6,CD66b Antigen,NCA-95,CD67,Carcinoembryonic antigen CGM6,CD66b,CEACAM8,Carcinoembryonic Antigen Related Cell Adhesion Molecule 8,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8,CD67 Antigen,CEA Cell Adhesion Molecule 8
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
CE8-H82E9 Human Biotinylated Human CEACAM-8 / CD66b Protein, His,Avitag™
CE8-H82E9-structure
CE8-H82E9-sds
CE8-H5224 Human Human CEACAM-8 / CD66b Protein, His Tag
CE8-H5224-structure
CE8-H5224-sds
ACRO Quality

Part of Bioactivity data

CE8-H5224-ELISA
 CEACAM-8 ELISA

Immobilized Human CEACAM-8, His Tag (Cat. No. CE8-H5224) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-6, His,Avitag (Cat. No. CE6-H82E7) with a linear range of 0.078-1.25 μg/mL (QC tested).

CE8-H82E9-ELISA
 CEACAM-8 ELISA

Immobilized Human CEACAM-6, His Tag (Cat. No. CE6-H5223) at 10 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-8, His,Avitag (Cat. No. CE8-H82E9) with a linear range of 0.02-0.313 μg/mL (QC tested).

Synonym Name

CEACAM8,CD66b,CD67,CGM6,NCA-95

Background

Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) is also known as CD66b (Cluster of Differentiation 66b), CD66b, CD67, CGM6, NCA-95, and is one of seven human CEACAM family members within the immunoglobulin superfamily. CEACAM family members are a set of widely expressed proteins involved in several biological functions, including cell adhesion, migration, signal transduction, and the regulation of gene expression. Abnormal overexpression and downregulation of some CEACAMs have been described in tumor cells. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM8 is a single chain, two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It is an activation marker for human granulocytes.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Besilesomab BW-250-183; 99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx Approved Cis Bio International Sa Scintimun EU Osteomyelitis Cis Bio International Sa 2010-01-11 Osteomyelitis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
90Y-DTPA-besilesomab TLX-66 Phase 2 Clinical Telix Pharmaceuticals Ltd Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell Details

This web search service is supported by Google Inc.

totop

Nachricht schicken